Filing Details
- Accession Number:
- 0001209191-11-002497
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-01-07 17:23:50
- Reporting Period:
- 2011-01-05
- Filing Date:
- 2011-01-07
- Accepted Time:
- 2011-01-07 17:23:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 858803 | Avanir Pharmaceuticals Inc. | AVNR | Pharmaceutical Preparations (2834) | 330314804 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1350416 | Randall Kaye | 101 Enterprise, Suite 300 Aliso Viejo CA 92656 | Sr. Vp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2011-01-05 | 10,000 | $4.05 | 165,690 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 6,250 | Indirect | By son |
| Common Stock | 6,250 | Indirect | By daughter |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2010 and the proceeds from such sales were used in part to pay required tax withholdings due upon vesting of restricted stock units previously granted to the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.0500 to $4.0505, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Billionaire Hedge Funds
